Novartis bid to sell new biosimilar crimped by U.S. court battles – Business Insider

Novartis bid to sell new biosimilar crimped by U.S. court battles
Business Insider
ZURICH (Reuters) – Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion in annual U.S. revenue remains blocked by court battles. Novartis’s …
Novartis Just Got Some Great News in Its Battle for Amgen’s Market ShareFortune
Novartis Taps Biosimilar Experience in Europe to Snag U.S. SalesBloomberg
FDA Approves New Biological Drug for Rheumatoid ArthritisGlens Falls Post-Star
FDA.gov –FierceBiotech –ModernHealthcare.com –Fox News
all 77 news articles »